PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer

Oncogene

Volumn 35, Issue 23, 2016, Pages 3004-3015

  Fan, S J ^a   Snell, C ^b   Turley, H ^b   Li, J L ^b   McCormick, R ^b   Perera, S M W ^a   Heublein, S ^a   Kazi, S ^a   Azad, A ^a   Wilson, C ^a   Harris, A L ^b   Goberdhan, D C I ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTON ASSISTED AMINO ACID TRANSPORTER 4; RAPAMYCIN; SERINE; TUMOR PROTEIN; UNCLASSIFIED DRUG; AMINO ACID; AMINO ACID TRANSPORTER; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER SURGERY; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GOLGI COMPLEX; HCT116 CELL LINE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETICS; HCT 116 CELL LINE; METABOLISM; NUDE MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AMINO ACID TRANSPORT SYSTEMS; AMINO ACIDS; ANIMALS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GOLGI APPARATUS; HCT116 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84973610952     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.363     Document Type: Article

References (43)

1. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012; 491: 364-373.
2. Bar-Peled L, Sabatini DM. Regulation of mTORC1 by amino acids. Trends Cell Biol 2014; 24: 400-406.
3. Malik AR, Urbanska M, Macias M, Skalecka A, Jaworski J. Beyond control of protein translation: What we have learned about the non-canonical regulation and function of mammalian target of rapamycin (mTOR). Biochim Biophys Acta 2012; 1834: 1434-1448.
4. Jewell JL, Guan KL. Nutrient signaling to mTOR and cell growth. Trends Biochem Sci 2013; 38: 233-242.
5. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett 2012; 319: 1-7.
6. Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 2012; 11: 594-603.
7. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 2010; 16: 4914-4920.
8. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55-61.
9. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012; 485: 109-113.
10. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S et al. A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 2014; 4: 554-563.
11. Thwaites DT, Anderson CM. The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport. Br J Pharmacol 2011; 164: 1802-1816.
12. Goberdhan DC, Meredith D, Boyd CA, Wilson C. PAT-related amino acid transporters regulate growth via a novel mechanism that does not require bulk transport of amino acids. Development 2005; 132: 2365-2375.
13. Ogmundsdottir MH, Heublein S, Kazi S, Reynolds B, Visvalingam SM, Shaw MK et al. Proton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes. PLoS One 2012; 7: e36616.
14. Heublein S, Kazi S, Ogmundsdottir MH, Attwood EV, Kala S, Boyd CA et al. Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation. Oncogene 2010; 29: 4068-4079.
15. Sagne C, Agulhon C, Ravassard P, Darmon M, Hamon M, El Mestikawy S et al. Identification and characterization of a lysosomal transporter for small neutral amino acids. Proc Natl Acad Sci USA 2001; 98: 7206-7211.
16. +-coupled electrogenic lysosomal amino acid transporter LYAAT1 localizes to the axon and plasma membrane of hippocampal neurons. J Neurosci 2003; 23: 1265-1275.
17. Goberdhan DC. Intracellular amino acid sensing and mTORC1-regulated growth: new ways to block an old target? Curr Opin Invest Drugs 2010; 11: 1360-1367.
18. Wang S, Tsun ZY, Wolfson RL, Shen K, Wyant GA, Plovanich ME et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 2015; 347: 188-194.
19. Rebsamen M, Pochini L, Stasyk T, de Araújo ME, Galluccio M, Kandasamy RK et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 2015; 19: 477-481.
20. Thomas JD, Zhang YJ, Wei YH, Cho JH, Morris LE, Wang HY et al. Rab1A is an mTORC1 activator and a colorectal oncogene. Cancer Cell 2014; 26: 754-769.
21. Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Plouffe SW et al. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Science 2015; 347: 194-198.
22. Xu L, Salloum D, Medlin PS, Saqcena M, Yellen P, Perrella B et al. Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). J Biol Chem 2011; 286: 25477-25486.
23. Yoon MS, Du G, Backer JM, Frohman MA, Chen J. Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway. J Cell Biol 2011; 195: 435-447.
24. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-117.
25. Kim DD, Eng C. The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opin Invest Drugs 2012; 21: 1775-1788.
26. Jiang P, Du W, Mancuso A, Wellen KE, Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013; 493: 689-693.
27. Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013; 493: 542-546.
28. Constantinou C, Clemens MJ. Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53. Oncogene 2005; 24: 4839-4850.
29. Karim MM, Hughes JM, Warwicker J, Scheper GC, Proud CG, McCarthy JE. A quantitative molecular model for modulation of mammalian translation by the eIF4E-binding protein 1. J Biol Chem 2001; 276: 20750-20757.
30. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014; 33: 1590-1600.
31. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532.
32. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 2011; 334: 678-683.
33. Söderberg O, Gullberg M, Jarvius M, Riddersträle K, Leuchowius K-J, Jarvius J et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995-1000.
34. Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 2013; 341: 1236566.
35. Li L, Kim E, Yuan H, Inoki K, Goraksha-Hicks P, Schiesher RL et al. Regulation of mTORC1 by the Rab and Arf GTPases. J Biol Chem 2010; 285: 19705-19709.
36. Matsui T, Fukuda M. Rab12 regulates mTORC1 activity and autophagy through controlling the degradation of amino-acid transporter PAT4. EMBO Rep 2013; 14: 450-457.
37. Pillai SM, Meredith D. SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J Biol Chem 2011; 286: 2455-2460.
38. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534.
39. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011; 71: 6073-6083.
40. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010; 141: 290-303.
41. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007; 67: 11244-11253.
42. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001; 195: 72-79.
43. Rath A, Glibowicka M, Nadeau VG, Chen G, Deber CM. Detergent binding explains anomalous SDS-PAGE migration of membrane proteins. Proc Natl Acad Sci USA 2009; 106: 1760-1765.